Non-Alcoholic Steatohepatitis Treatment Market to Grow with a CAGR of 39.30% through 2029
Increase in the incidence of Non-Alcoholic
Steatohepatitis and unmet medical needs is expected to drive the Global Non-Alcoholic
Steatohepatitis Treatment Market growth in the forecast period, 2025-2029.
According to
TechSci Research report, “Non-Alcoholic Steatohepatitis Treatment Market – Global
Industry Size, Share, Trends, Competition Forecast & Opportunities, 2029F”,
the Global Non-Alcoholic Steatohepatitis Treatment Market stood at USD 1.15
billion in 2023 and is anticipated to grow with a CAGR of 39.30% in the
forecast period through 2029. Increased awareness among individuals regarding Non-Alcoholic Steatohepatitis (NASH) treatment has created favorable market conditions for the global NASH treatment market. Several factors are driving the growth of various NASH treatment products.
The global prevalence of NASH is on the rise due to increasing rates of obesity, metabolic syndrome, and type 2 diabetes. These conditions are significant risk factors for NASH development, resulting in a larger patient pool seeking treatment. Enhanced awareness of NASH among healthcare professionals and the general population has led to higher rates of diagnosis. As awareness continues to grow, more patients are identified and seeking treatment. There is a notable unmet medical need in NASH treatment, particularly for patients in advanced disease stages. This necessity fuels research and development endeavors aimed at discovering and developing effective therapies, thereby contributing to market expansion.
The main objective of treating Non-Alcoholic Steatohepatitis (NASH) is to halt disease progression and mitigate liver inflammation and damage. NASH represents an advanced stage of non-alcoholic fatty liver disease (NAFLD), characterized by liver cell inflammation and injury. Left untreated, NASH can escalate to severe liver conditions such as fibrosis and cirrhosis, ultimately leading to liver failure, thus driving market growth. Fibrosis involves the accumulation of scar tissue in the liver, while cirrhosis denotes advanced scarring. NASH treatment aims to prevent or minimize fibrosis and cirrhosis development, given their potential for significant liver dysfunction and complications. The increasing recognition of the benefits of NASH treatment is expected to positively impact the global NASH treatment market.
NASH treatment is pivotal in our modern society, addressing health risks associated with the condition and enhancing affected individuals' quality of life. As NASH is closely linked with obesity, metabolic syndrome, and unhealthy lifestyles prevalent in contemporary societies, treatment focuses on impeding disease progression to severe stages like advanced fibrosis or cirrhosis. In a fast-paced world where individuals prioritize work and other commitments, early health issue management is crucial to avoid future complications. NASH treatment aids in leading healthier lives long-term by managing risk factors such as obesity, diabetes, and metabolic syndrome, thus reducing the likelihood of chronic disease development. By addressing NASH early, the need for intensive medical interventions in the future can be averted, potentially alleviating healthcare system burdens and enabling uninterrupted daily lives.
Pharmaceutical companies are heavily investing in researching and developing new drugs and therapies for NASH treatment. This includes exploring novel mechanisms targeting inflammation, fibrosis, and metabolic pathways associated with NASH.
Although there were no FDA-approved medications specifically for NASH treatment previously, various interventions were under exploration to manage the condition and its risks. Lifestyle modifications, such as adopting a healthy diet and increasing physical activity, remain fundamental in NASH management. While no FDA-approved medications for NASH treatment were available, multiple drug classes were undergoing clinical trials. However, challenges related to natural vitamin raw material scarcity may impede market growth, alongside ingredient shortages and price sensitivity posing potential obstacles to the vitamins market in the near future.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Non-Alcoholic Steatohepatitis Treatment Market”
The Global Non-Alcoholic
Steatohepatitis Treatment Market is segmented into drug type, end-user, and
company.
Based on end user, The retail and specialty pharmacy segment is projected to experience rapid growth during the forecast period. Retail pharmacies are easily accessible to the general population, making them a convenient option for patients seeking NASH treatments. They are often located in communities and can provide a wide range of prescription medications, including those used for NASH. Retail pharmacies dispense medications prescribed by healthcare providers. They play a crucial role in providing patients with the medications they need to manage chronic conditions like NASH. Specialty pharmacies specialize in medications for complex and chronic conditions like NASH. They have pharmacists and staff with expertise in managing specialty medications, which may include NASH treatments that require special handling or administration. Specialty pharmacies often provide comprehensive support programs for patients using specialty medications. This can include services like medication delivery, financial assistance, and coordination with healthcare providers. These factors collectively contribute to the growth of this segment.
Based on region, In 2023, North America emerged as the leading region in the global Non-Alcoholic Steatohepatitis (NASH) Treatment market, capturing the largest market share by value. The United States, in particular, is significantly impacted by obesity, type 2 diabetes, and metabolic syndrome, which are major risk factors for NASH. This high prevalence has resulted in a larger at-risk population for developing NASH. The region benefits from well-established healthcare systems, featuring advanced medical facilities, specialized clinics, and access to cutting-edge diagnostic and treatment technologies. This robust infrastructure supports early diagnosis and comprehensive management of NASH. Additionally, North America is a key center for clinical research and pharmaceutical innovation, with numerous research institutions, academic centers, and pharmaceutical companies actively involved in the development and testing of NASH treatments. The healthcare education systems in the United States and Canada effectively raise awareness about chronic diseases like NASH, leading to early detection, diagnosis, and timely treatment initiation. The North American pharmaceutical industry has shown substantial interest in NASH research and drug development, resulting in significant clinical trials, investments, and collaborations aimed at bringing NASH therapies to market.
Major companies
operating in Global Non-Alcoholic Steatohepatitis Treatment Market
are:
- Intercept
Pharmaceuticals Inc.
- Galmed
Research & Development Ltd.
- INVENTIVA
S.A.
- AbbVie
Inc.
- Galectin
Therapeutics Inc.
- Madrigal
Pharmaceuticals Inc.
- NGM
Biopharmaceuticals Inc.
- Novo
Nordisk A/S
- Bristol
Myers Squibb
- Gilead Sciences Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Lifestyle
Changes and Obesity Epidemic and Increasing Healthcare Expenditure are key
drivers of the NASH market. In recent years, With increasing awareness of
NASH's potential consequences, patients are becoming more proactive in seeking
appropriate treatment options to manage their condition and prevent disease
progression. Moreover, the growing consumer emphasis on preventative healthcare
products has enhanced production and marketing efforts. To meet the demands of
the market, manufacturers are increasingly incorporating cutting-edge
technologies with high production efficiency. Rising consumer acceptance and
continuous product innovation will further ensure the growth of the vitamins
and supplements market in the coming years.,” said Mr. Karan Chechi, Research
Director, TechSci Research, a research-based management consulting firm.
“Non-Alcoholic Steatohepatitis Treatment Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Lanifibranor, Semaglutide, Resmetirom, Aramchol, Cenicriviroc, Others), By End-User (Hospital Pharmacies, Retail and Specialty Pharmacies, Others), By Region, Competition, 2019-2029F”,
has evaluated the future growth potential of Global Non-Alcoholic
Steatohepatitis Treatment Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Non-Alcoholic
Steatohepatitis Treatment Market.
Contact
TechSci Research LLC
420 Lexington Avenue,
Suite 300, New York,
United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com